Humacyte, Inc. (HUMAW)
2025-06-30 | ||||
|---|---|---|---|---|
| Total revenue | 301 | |||
| Selling, general and administrative | 7,809 | |||
| Research and development | 22,006 | |||
| Cost of goods sold | 213 | |||
| Total operating expenses | 30,028 | |||
| Loss from operations | -29,727 | |||
| Change in fair value of derivatives | -748 | |||
| Interest income | 832 | |||
| Interest expense | 2,545 | |||
| Change in fair value of contingent earnout liability | 5,470 | |||
| Total other income (expense), net | -7,931 | |||
| Net income (loss) | -37,658 | |||
| Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | -0.24 | |||
| Net income (loss) per share attributable to common stockholders, diluted (in dollars per share) | -0.24 | |||
| Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, basic (in shares) | 155,437,281 | |||
| Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, diluted (in shares) | 155,437,281 | |||